Oral rapamycin in the treatment of patients with hamartoma syndromes and PTEN mutation
Authors:
- 25 February 2011
- journal article
- case report
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 57 (2) , 321-323
Abstract
Bannayan–Riley–Ruvacalba syndrome (BRRS) belongs to the PTEN hamartoma tumor syndromes and is characterized by a high risk of malignancy in early adulthood added to local destructive effects of hamartomas in childhood. There is no standard treatment for this condition and patients are usually offered symptomatic surgical relief. Rapamycin has been reported to be effective in the management of other conditions associated with PTEN mutation. We report here a case of BRRS in a 6‐year‐old male with progressive loss of function of left hand and forearm associated with pain. He was treated with oral rapamycin and regained pain‐free full mobility. Pediatr Blood Cancer 2011; 57: 321–323.Keywords
This publication has 6 references indexed in Scilit:
- PTEN hamartoma tumor syndrome: An overviewGenetics in Medicine, 2009
- PTEN hamartoma tumor syndromesEuropean Journal of Human Genetics, 2008
- Rapamycin treatment for a child with germline PTEN mutationNature Clinical Practice Oncology, 2008
- Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or LymphangioleiomyomatosisNew England Journal of Medicine, 2008
- The spectrum of vascular anomalies in patients with PTEN mutations: implications for diagnosis and managementJournal of Medical Genetics, 2007
- Dysregulation of the TSC-mTOR pathway in human diseaseNature Genetics, 2004